LIVN - LivaNova PLC
81.48 0.00 (0.00%)
After hours: 4:59PM EDT
| Previous Close | 79.46 |
| Open | 80.25 |
| Bid | 81.60 x 1100 |
| Ask | 81.61 x 1100 |
| Day's Range | 80.23 - 81.68 |
| 52 Week Range | 64.80 - 131.54 |
| Volume | 294,206 |
| Avg. Volume | 385,961 |
| Market Cap | 3.943B |
| Beta (3Y Monthly) | 0.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.41 |
| Earnings Date | Oct 29, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 92.29 |
Motley FoolLivaNova PLC (LIVN) Q2 2019 Earnings Call Transcript
LIVN earnings call for the period ending June 30, 2019.
- Zacks
LivaNova (LIVN) Q2 Earnings and Revenues Surpass Estimates
LivaNova (LIVN) delivered earnings and revenue surprises of 2.94% and 1.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
LivaNova Reports Second Quarter 2019 Results
LivaNova PLC , a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2019.
- Zacks
Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More
Solid growth in emerging markets is expected to be an added positive this earnings season.
- Zacks
Analysts Estimate LivaNova (LIVN) to Report a Decline in Earnings: What to Look Out for
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Is There An Opportunity With LivaNova PLC's (NASDAQ:LIVN) 25% Undervaluation?
Today we will run through one way of estimating the intrinsic value of LivaNova PLC (NASDAQ:LIVN) by taking the...
- Business Wire
LivaNova Combats Leg Ischemia with Breakthrough Bidirectional Cannula
LivaNova PLC (LIVN), a market-leading medical technology company, today launched its innovative arterial femoral cannula, Bi-Flow, designed to prevent limb ischemia during cardiac surgery. LivaNova Bi-Flow received CE Mark earlier this year and is the only bidirectional arterial cannula designed to prevent leg ischemia during cardiac surgery procedures requiring femoral artery cannulation.
- Business Wire
LivaNova Receives U.S. FDA 510(k) Clearance for LifeSPARC Advanced Circulatory Support System
LivaNova PLC (LIVN), a market-leading medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Advanced Circulatory Support (ACS) pump and controller, the LifeSPARC system. Derived from more than 20 years of life support experience with TandemLife, LifeSPARC begins a new chapter for ACS innovation within the LivaNova portfolio.
- Business Wire
LivaNova Celebrates 25 Years of Vagus Nerve Stimulation Therapy
LivaNova PLC (LIVN), a market-leading medical technology company, is celebrating the 25th anniversary of its Vagus Nerve Stimulation Therapy® (VNS Therapy) System. This clinically proven, safe and effective therapy is used for the treatment of Drug-Resistant Epilepsy (DRE), Treatment-Resistant Depression (TRD) and for the delivery of Autonomic Regulation Therapy for Heart Failure. “Celebrating 25 years of VNS Therapy is a significant milestone not only for our company, but for each patient VNS Therapy helps every day,” said Damien McDonald, Chief Executive Officer of LivaNova.
- Insider Monkey
Here’s What Hedge Funds Think About LivaNova PLC (LIVN)
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
- Business Wire
LivaNova Welcomes Stacy Enxing Seng to Board of Directors
LivaNova PLC , a market-leading medical technology company, today announced that Stacy Enxing Seng, a Venture Partner with Lightstone Ventures and former executive at several healthcare and medical technology companies, was elected by the Company’s shareholders to join its Board of Directors during its June 18 annual general meeting.
- Business Wire
LivaNova to Host Conference Call for Second Quarter 2019 Results
LivaNova PLC (LIVN), a market-leading medical technology company, will host a conference call to discuss its second quarter 2019 results on Wednesday, July 31, 2019 at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second quarter 2019 results prior to the call. A live webcast of the conference call will be available on the Investor Relations section of the LivaNova website at www.livanova.com.
- Markit
See what the IHS Markit Score report has to say about LivaNova PLC.
LivaNova PLC NASDAQ/NGS:LIVNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for LIVN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding LIVN totaled $420 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire
LivaNova to Present at the UBS Global Healthcare Conference
LivaNova PLC (LIVN), a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer, and Thad Huston, Chief Financial Officer, will present at the UBS Global Healthcare Conference on Wednesday, May 22 in New York at 10 a.m. Eastern Time. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world.
- Business Wire
New Data Emphasizing LivaNova Perceval Valve Durability to be Presented at the American Association for Thoracic Surgery Meeting
LivaNova PLC (LIVN), a market-leading medical technology company, today announced that new clinical data for its sutureless surgical aortic valve, Perceval®, will be unveiled at this year’s American Association for Thoracic Surgery (AATS) meeting. On May 4, Prof. Bart Meuris from Leuven University Hospital (BE) will present the data from his center’s 11-year clinical experience with Perceval, which represents the longest clinical follow-up for the valve that has been published. Of particular significance in the findings is the absence of explants due to structural valve deterioration (SVD), as well as the low rate of paravalvular leak (PVL) reported.
- Motley Fool
Livanova (LIVN) Q1 2019 Earnings Call Transcript
LIVN earnings call for the period ending March 31, 2019.
- Associated Press
LivaNova: 1Q Earnings Snapshot
On a per-share basis, the London-based company said it had a loss of 31 cents. Earnings, adjusted for non-recurring costs and amortization costs, were 54 cents per share. The results exceeded Wall Street ...
- Business Wire
LivaNova Reports First Quarter 2019 Results
LivaNova PLC , a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2019.
- Insider Monkey
Were Hedge Funds Right About Fleeing LivaNova PLC (LIVN)?
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]
- Associated Press
Snap and Apache jump while Boston Beer, LivaNova slip
Stocks that moved substantially or traded heavily on Friday: Duluth Holdings Inc., down $5.94 to $17.60 The clothing retailer's fourth-quarter profit and revenue fell short of Wall Street forecasts. LivaNova ...
- Motley Fool
Why Duluth Holdings, LivaNova, and Boston Beer Slumped Today
These stocks lost ground even as the broader market posted solid gains.
- Motley Fool
Here's Why LivaNova Plummeted Today
The medical-device company posted tepid preliminary first-quarter revenue.
